Klaus Pantel
Klaus Pantel is a pioneer of circulating tumour cell research and the liquid biopsy field.
Klaus Pantel's work on disseminated and circulating tumour cells established liquid biopsy as a research discipline; he coordinated the European CANCER-ID consortium.
| Title | Journal | Year |
|---|---|---|
| Liquid biopsy and minimal residual disease: latest advances and implications for cure | Nature Reviews Clinical Oncology | 2019 |
Pages like this
not linked directly; found by shared links- PersonMaximilian Diehn
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- PersonAsh A. Alizadeh
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- CompanyPersonalis (Tempus)
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- IdeaHPV circulating tumour DNA to guide cervical cancer therapy
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- IdeactDNA-triggered escalation in early TNBC
Shares A ring-fenced metastasis programme with metastasis-specific endpoints, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
- IdeaBlock the recycling that keeps dormant cells alive
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- IdeaBank yearly blood from cancer survivors so future tests can be validated
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- IdeaCertified reference samples to benchmark every tumour-DNA blood test
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).